Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
NCT06532591
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
NSCLC
Interventions
DRUG:
cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin
Sponsor
Sichuan Cancer Hospital and Research Institute